4038 Federal Register / Vol. 74, No. 13 / Thursday, January 22, 2009 / Notices 

officers promptly respond to this report 

by meeting the incoming conveyance 

(when possible), collecting information 

and evaluating the patient(s), and 

determining whether an ill person can 

safely be admitted into the U.S. If 

Quarantine Station staff are unable to 

meet the conveyance, the crew or 

medical staff of the conveyance are 

trained to complete the required 

documentation and forward it (using a 

secure system) to the Quarantine Station 

for review and follow-up. 

To perform these tasks in a 

streamlined manner and ensure that all 

relevant information is collected in the 

most efficient and timely manner 

possible, Quarantine Stations use a 

number of forms—the Airline Screening 

and Illness Response Form, the Ship 

Illness/Death Reporting Form, and the 

Land/Border Crossing Form—to collect 

data on passengers with suspected 

illness and other travelers/crew who 

may have been exposed to an illness. 

These forms are also used to respond to 

a report of a death aboard a conveyance. 

The purpose of all of the forms is the 

same: to collect information that helps 

quarantine officials detect and respond 

to potential public health 

communicable disease threats. All forms 

collect the following categories of 

information: demographics and mode of 

transportation, clinical and medical 

history, and any other relevant facts 

(e.g., travel history, traveling 

companions, etc.). As part of this 

documentation, quarantine public 

health officers look for specific signs 

and symptoms common to the nine 

quarantinable diseases (Pandemic 

influenza; SARS; Cholera; Plague; 

Diphtheria; Infectious Tuberculosis; 

Smallpox; Yellow fever; and Viral 

Hemorrhagic Fevers), as well as most 

communicable diseases in general. 

These signs and symptoms include 

fever, difficulty breathing, shortness of 

breath, cough, diarrhea, jaundice, or 

signs of a neurological infection. The 

forms also collect data specific to the 

traveler’s conveyance. 

These data are used by Quarantine 

Stations to make decisions about a 

passenger’s suspected illness as well as 

its communicability. This in turn 

enables Quarantine Station staff to assist 

conveyances in the public health 

management of passengers and crew. 

The estimated total burden on the 

public, included in the chart below, can 

vary a great deal depending on the 

severity of the illness being reported, 

the number of contacts, the number of 

follow-up inquiries required, and who is 

recording the information (e.g., 

Quarantine Station staff versus the 

conveyance medical authority). In all 

cases, Quarantine Stations have 

implemented practices and procedures 

that balance the health and safety of the 

American public against the public’s 

desire for minimal interference with 

their travel and trade. Whenever 

possible, Quarantine Station staff obtain 

information from other documentation 

(e.g., manifest order, other airline 

documents) to reduce the amount of the 

public burden. 

There is no cost to respondents other 

than their time to complete the survey. 

The total estimated annualized burden 

for this data collection is 172 hours. 

ESTIMATE OF ANNUALIZED BURDEN

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Airline Illness or Death Investigation Form ................................................................................. 1320 1 6/60 

International Maritime Illness or Death Report ............................................................................ 200 1 3/60 

International Maritime Illness or Death Investigation Form ......................................................... 200 1 7/60 

Land Border Illness or Death Investigation Form ....................................................................... 60 1 6/60

Dated: January 12, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–1225 Filed 1–21–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–09–0691] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

State Medicaid Tobacco Coverage 

Survey—Reinstatement—National 

Center for Chronic Disease Prevention 

and Control (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Tobacco use remains the leading 

preventable cause of death in the United 

States despite the availability of 

evidence-based treatments for tobacco 

dependence, which include counseling 

and FDA-approved pharmacotherapies. 

To increase both the use of treatment by 

smokers attempting to quit and the 

number of smokers who quit 

successfully, the Guide to Community 

Preventive Services recommends 

reducing the out-of-pocket cost of 

effective tobacco-dependence 

treatments, and the Public Health 

Service (PHS) Clinical Practice 

Guideline supports expanded insurance 

coverage for tobacco-dependence 

treatment. 

Medicaid recipients have 

approximately 50% greater smoking 

prevalence than the overall U.S. adult 

population, and they are 

disproportionately affected by tobaccorelated disease and disability. 

Information about the amount and type 

of coverage for tobacco-dependence 

treatment offered by Medicaid has been 

collected during 1998, 2000, 2001, 2002, 

2003, 2005, 2006, and 2007. Information 

collection for the three most recent 

years (2005–2007) was conducted by the 

Centers for Disease Control and 

Prevention (OMB No. 0920–0691, 

expiration date 8/31/2008). Respondents 

were Medicaid directors or their 

designees in all 50 states and the 

District of Columbia. 

CDC requests OMB approval to 

reinstate information collection for an 


rmajette on PRODPC74 with NOTICES
Federal Register / Vol. 74, No. 13 / Thursday, January 22, 2009 / Notices 4039 

additional three-year period. Responses 

will be submitted electronically using a 

web-based survey instrument. Minor 

changes to the instrument are proposed 

to address compliance with 

recommendations made in the updated 

PHS clinical practice guideline issued 

in May of 2008, such as coverage for 

combination therapies, smokeless 

tobacco use, and states’ familiarity with 

and use of the 2000 PHS guideline. The 

minor changes are not expected to affect 

the overall burden estimate. To 

minimize burden, each respondent will 

only be asked to record changes that 

occurred since the time of the previous 

submission. As in previous years, each 

respondent will also attach a copy of the 

state’s Medicaid coverage plan to their 

completed survey, in order to assist the 

research team with the interpretation of 

responses. 

The information to be collected will 

allow CDC to continue monitoring 

compliance with the most recent PHS 

recommendations and the progress of 

State Medicaid Programs toward the 

2010 National Health Objectives and 

Healthy People 2010 goals. 

There are no costs to respondents 

except the time to complete the survey. 

The total estimated burden hours are 26. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

State Medicaid Programs ............................................................................................................ 51 1 30/60 

Dated: January 13, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–1227 Filed 1–21–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

The National Institute for Occupational 

Safety and Health (NIOSH) of the 

Centers for Disease Control and 

Prevention (CDC) Announces an 

Evaluation of Downdraft Vented Nail 

Salon Tables (VNTs) 

Authority: 29 U.S.C. Sections 651 et seq. 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Division of Applied 

Research and Technology (DART), 

NIOSH, is conducting an evaluation of 

downdraft vented salon nail tables 

(VNTs). This notice invites developers, 

manufacturers, and vendors of VNTs to 

submit new, unused, downdraft VNTs 

for evaluation of operational 

characteristics and effectiveness in 

reducing levels of a source point tracer 

gas at standard distances from the vent. 

A 6-month supply of manufacturer 

recommended filters is to be submitted 

to NIOSH at the address below, together 

with the VNT. 

Evaluation parameters for the VNTs 

will include, but are not limited to: 

Airflow and capture characteristics, 

noise level, ergonomic features, and 

filter life. Manufacturers, vendors, and 

developers who wish to submit VNTs 

with filters for evaluation are invited to 

respond to this announcement. A report 

on each VNT submitted for evaluation, 

including feedback on the evaluation 

parameters and staff recommendations, 

will be sent to the submitter. Results of 

the evaluation will potentially be used 

to develop educational materials for nail 

technicians and may also be 

disseminated through reports, 

publications, or presentations. NIOSH 

does not intend to identify 

manufacturers in its publications but 

testing information referencing 

particular manufacturers would be 

releasable if requested under the 

Freedom of Information Act (FOIA). 

DATES: Written letter of interest must be 

received within 90 calendar days of 

publication in the Federal Register. The 

deadline for receipt of VNT and filter 

submissions is June 30, 2009. 

Evaluations will begin subject to the 

dates VNT and filter submissions are 

received. The VNTs will be retained for 

up to 10 months while being evaluated, 

after which they will be returned. 

ADDRESSES: Manufacturers, vendors, 

and developers who wish to submit 

VNTs with filters for evaluation are 

invited to respond to this 

announcement by sending a written 

letter of interest to NIOSH/DART, 

Robert A. Taft Laboratories, 4676 

Columbia Parkway, Mailstop C–23, 

Cincinnati, Ohio 45226, Attention: 

Susan Reutman, e-mail address: 

SReutman@cdc.gov. 

SUPPLEMENTARY INFORMATION: Responses 

shall include: A description of the VNT 

including the manufacturer, schedule of 

availability of the VNT and filters for 

evaluation, and a statement of the terms 

under which the VNT will be made 

available for evaluation. Shipping and 

handling costs (including insurance) to 

ship the VNTs to NIOSH and for NIOSH 

to return the VNTs to the submitter will 

be the responsibility of the submitter. 

NIOSH reserves the right to decide 

which VNT submissions will be 

evaluated based on compliance with the 

specifications described above. NIOSH 

also reserves the right not to proceed in 

this manner. 

Note: As a government entity, we cannot 

endorse any specific product directly, 

indirectly, or by implication. NIOSH will not 

be responsible for any costs related to usage, 

wear and tear or accidental damage to the 

VNT during transport or while the VNT is at 

NIOSH. 

Contact Person for Technical 

Information: Susan Reutman, Ph.D., 

telephone (513) 533–8286, or e-mail 

SReutman@cdc.gov. 

Dated: January 2, 2009. 

James D. Seligman, 

Chief Information Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E9–1193 Filed 1–21–09; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–D–0264] 

Compliance Policy Guide Sec. 

540.370—Fish and Fishery Products— 

Decomposition; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 


rmajette on PRODPC74 with NOTICES